HCPLive Network

Hepatitis C

The US Senate Finance Committee recently requested detailed pricing information on Sovaldi (sofosbuvir), its breakthrough oral treatment for hepatitis C.
Japanese regulators have approved an all-oral daclatsvir plus asunaprevir drug regimen developed by Bristol-Meyers Squibb to treat patients with genotype 1 chronic hepatitis C.
Stephen Vogt, PharmD, Chief Executive Officer and President of BioPlus Specialty Pharmacy, discusses the ongoing debate surrounding the high price of Hepatitis C treatments versus the efficacy of the drug.
A recent study found that the hepatitis C virus decays during treatment with telaprevir faster in the bloodstream than it does in the liver, a discovery that could help pinpoint how long a patient needs to take medicine to rid the virus from the body.
Most children with hepatitis C contract the virus through transmission from their chronically infected mothers, either in the womb or at birth, particularly when an expectant mother also is HIV-positive.
The FDA has granted priority review for a New Drug Application submitted by AbbVie Inc. for its all-oral, interferon-free therapy for patients with chronic genotype 1 hepatitis C virus infection.